Close

Search

Subscribe
Browse Tag

ADC

18 Articles
Illustration of a labeled Tam-Peli ADC binding to a cancer-cell receptor on the left, with translucent lungs and a highlighted tumor on the right.

Roche and MediLink’s Tam-Peli Reduces Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial

By Xiaoxin Du
No Comments on Roche and MediLink’s Tam-Peli Reduces Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial
4 Min Read

Roche and MediLink Therapeutics have reported a substantial survival benefit for tambotatug pelitecan, the experimental B7-H3-targeted antibody-drug conjugate known as Tam-Peli, in patients with relapsed small-cell lung cancer. In the Chinese Phase 3…

Illustration of iza-bren above EGFR and HER3 receptors on a lung cancer cell, with labeled targets and golden drug payloads.

Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose

By Chris Chen
No Comments on Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
4 Min Read

Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…

Illustration of lungs with a tumor and a magnified antibody-drug conjugate labeled B7-H3 ADC binding to a cancer cell.

GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial

By Henry Tseng
No Comments on GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
5 Min Read

GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…

TQB2102 HER2 bispecific antibody-drug conjugate targeting HER2-low breast cancer cells and delivering a cytotoxic payload into the tumor cell.

CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing

By Henry Tseng
No Comments on CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
6 Min Read

Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…

CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing

By Chris Chen
No Comments on CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing
8 Min Read

CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in…

DualityBio Partners with Genentech in $1B-Plus Next-Generation ADC Collaboration Built Around Novel Payload Platform

By Jonathan Li
No Comments on DualityBio Partners with Genentech in $1B-Plus Next-Generation ADC Collaboration Built Around Novel Payload Platform
7 Min Read

China’s Duality Biotherapeutics has signed a global research, development and licensing agreement with Roche’s Genentech to develop a new generation of antibody-drug conjugates designed to overcome resistance to payloads used in today’s…